Novel Therapies for Type 2 Diabetes and Obesity Summit

Kongressthemen
The wave of breakthrough therapies in drug-based management of obesity has triggered a renaissance in metabolic disorders. As GLP-1 receptor agonists establish a new gold standard in weight-loss and first-in-class therapies demonstrate additional benefit in type 2 diabetes, stakeholders are flooding in to redefine the metabolic landscape.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Brochure: https://go.evvnt.com/1541817-3?pid=4832

Speakers: Ashish Nimgaonkar, Founder and Chief Executive, Glyscend Therapeutics, Jacob Jeppesen, Vice President, Novo Nordisk, Jerry Colca, Chief Scientific Officer, Cirius Therapeutics, and more

https://go.evvnt.com/1541817-2?pid=4832

Frau Jade Faulkner